Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer - HALO

Study identifier:D0818R00007

ClinicalTrials.gov identifier:NCT04991051

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

HRDx-Ovarian. A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer.

Medical condition

Fallopian Tube Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Female

Actual enrollment

605

Study type

Observational

Age

18 Years +

Date

Study Start Date: 02 May 2021
Primary Completion Date: 15 Aug 2022
Study Completion Date: 15 Aug 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria